Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-label, Single-arm, Multicenter Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced/Refractory Solid Tumors

Next Previous
Trial Profile

A Phase 2, Open-label, Single-arm, Multicenter Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced/Refractory Solid Tumors

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nanrilkefusp alfa (Primary) ; Pembrolizumab (Primary)
  • Indications Colorectal cancer; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Skin cancer; Solid tumours; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms AURELIO-04
  • Sponsors SOTIO

Most Recent Events

  • 16 Dec 2024 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped: Due to lack of expected efficacy shown at the time of the interim analysis.
  • 13 Sep 2024 This trial has been completed in Hungary, according to the European Clinical Trials Database record.
  • 07 Aug 2024 Planned End Date changed from 14 Dec 2025 to 30 Nov 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top